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The search for a minimally invasive approach to the treatment
of Lower Urinary Tract Symptoms (LUTS) suggestive of
Benign Prostatic Hyperplasia (BPH) is probably as old as
Transurethral Resection of the Prostate (TURP). In an effort
to overcome the limitations and morbidities of TURP, and in
light of evidence suggesting that medical treatment for BPH
has a limited life-span, laser-based treatments have emerged
during the last decade. Photoselective Vaporization of the
Prostate (PVP) by the “GreenLight” KTP laser is considered
one of the most promising options, one that is constantly
evolving new technologies in prostate surgery. In this
overview of KTP laser usage in BPH treatment, we will briefly
discuss the evolution of this modality since it was first
introduced and focus on the available evidence regarding
safety, efficacy and cost parameters of its application.
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INTRODUCTION
The search for the optimal minimally invasive
technique for the treatment of LUTS associated
with BPH carries quite a history. Over the past 15
years, efforts have been taken to introduce an ideal
minimally invasive treatment option for benign
prostatic hyperplasia (BPH). Different treatment
modalities employing varied delivery systems to
create heat to treat the prostate have not shown
consistent or durable efficacy compared to the
reference standard, transurethral resection of the
prostate (TURP). Recent advancements in the field
of bipolar plasma-kinetic vaporization of the
prostate
1,2 and the emergence of alternative treatment
options for BPH
3 have made this goal even more
challenging than previously considered.
Some of the laser-based treatment modalities
exhibited promising results and were initially
welcomed with expectations and enthusiasm by
the urological community. Unfortunately, few
stood the test of time, and even fewer were able
to withstand the comparison to the long-standing
reference treatment for BPH, transurethral resection
of the prostate (TURP).
Recent advancements in laser technology,
together with the increasing demand for a mini-
mally invasive procedure to alleviate lower urinary
tract symptoms more safely and efficaciously than
TURP, have led to the introduction of photo-
selective vaporization of the prostate using the
“GreenLight” KTP laser. The purpose of this
review is to explain the basic principles of KTP
lasers in urology and address the current status of
the application of this modality in the treatment of
BPH.
DISCUSSION
The characteristics of the KTP laser and how they
apply to prostate surgery
All lasers are not created equal. Proof of this is
the vast difference in the characteristics and the
interactions between different laser beams and
tissues. By doubling the frequency of pulsed Nd:
YAG laser energy with a potassium-titanyl-
phosphate-KTP crystal, a 532-nm wavelength laser
is created which has substantially different laser-
tissue interaction properties compared with its
predecessor, the Nd : YAG. One main difference
lies in the fact that the 532-nm wavelength beam
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of the KTP laser rests within the visible green
region of the electromagnetic spectrum (Greenlight-
laser), unlike the 1064 nm Nd:YAG light beam,
which is within the infrared portion of the
electromagnetic spectrum.
4
The KTP laser beam can be fully transmitted
through aqueous irrigants but is highly absorbed
by hemoglobin inside prostatic tissue. This
selective absorption of the green KTP laser beam
by hemoglobin in tissue is the reason KTP laser
vaporization prostatectomy was named photoselec-
tive vaporization of the prostate (PVP). Absorption
leads to instant removal of prostatic tissue by a
rapid photothermal vaporization of heated
intracellular water.
5 Because of the short optical
penetration of the KTP laser into tissue (0.8 mm),
the resulting coagulation zone is limited (1 - 2
mm), which leads to a more focused and efficient
vaporization.
6
The KTP laser is used to effectively vaporize
prostatic adenomatous tissue and create an uno-
bstructed TURP-like cavity. For this reason, the
KTP laser fiber is delivered via a relatively
small-caliber scope (22 - 23F). PVP is performed in
a near-contact mode with a 70 degree side firing
fiber. A continuously emitted beam allows rapidly
progressive and efficient vaporization of glandular
tissue down to the prostatic capsule (where
vaporization efficiency of the laser is hampered by
the relatively hypovascular fibrous capsule). The
effectiveness of vaporization is judged by bubble
formation. Normal saline is usually used as an
irrigant, although water can also be used, without
however enhancing visualization.
7
The lack of significant absorption of the irrigation
fluid during PVP has already been proven by using
expired breath ethanol measurements; therefore,
there is no safety issue in using sterile water as an
irrigant for this procedure.
8
Haemostasis is achieved by the inherent
superficial coagulative effect of the KTP laser
beam, allowing for an almost bloodless procedure.
A coagulation zone thickness of only 1 to 2 mm
avoids the problems associated with earlier
Nd:YAG laser treatments in which much deeper
tissue coagulation necrosis (7 mm) led to severe
post-operative dysuria and delayed sloughing,
resulting in prolonged obstruction.
9
The evolution of KTP lasers for the treatment of
BPH
Most of the early data available addresses the
Nd : YAG laser coagulation. Visual laser ablation
of the prostate (VLAP), first introduced by
Costello using a 1064 nm Nd : YAG laser, was
used to apply the effects of coagulation to prostate
tissue.
10 The limitation of applying the technique
to small prostates, together with a prolonged
operative time, dysuric symptoms, and considerable
post-operative catheterization time due to massive
sloughing of necrotic tissue, did not add to its
reputation or durability.
11
Early experience: the “hybrid” techniques
KTP lasers were actually introduced in the
treatment of BPH in combination with already
existing laser modalities. These so-called ‘hybrid’
techniques were developed with the intention to
combine the coagulation and haemostatic effects
of the 1064 nm Nd:YAG laser with the excellent
excision and vaporization efficacy of the 532 nm
wavelength KTP laser. The use of the KTP laser
in conjunction with the Nd:YAG laser allows for
vaporization of more tissue, thus decreasing the
amount of tissue undergoing coagulation necrosis.
The KTP laser energy was used to perform a
bladder neck incision and, in some cases, to
vaporize any median lobe.
The rationale behind these ‘hybrid’ techniques
was that the additional incisions using the KTP
laser would decrease some of the aforementioned
problems faced when Nd : YAG techniques alone
were used; specifically, prolonged catheter drain-
age and troublesome dysuria. The use of the KTP
laser added only 15 minutes to the procedure. In
the KTP laser prostatectomy series originally
reported, a laser calibrated to 38 W was used, but,
in reality, it rarely delivered more than 20 W of
power. The vaporization procedure was lengthy,
tedious and often erratically performed.
4
The first description of KTP laser prostatectomy
came from Watson in 1995,
12 who utilized the 30
W KTP laser followed by Nd : YAG laser
coagulation. In a series of cases with short-term
follow-up, the technique was characterized as
safe; however, the rate of post-operative retentionThe Role of Lasers in the Treatment of benign Prostatic Hyperplasia
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and the delayed onset of therapeutic effects
continued to be an issue.
13 Comparison of low (20
W) to high power (40 W) KTP laser added to a
standard 60 W Nd : YAG ablation favored the 40
W KTP mainly because of a more rapid improve-
ment in symptoms.
14 Kollmorgen et al.,
15 in their
2.5 years follow-up of two groups of men under-
going VLAP (40 W Nd : YAG) compared to VLAP
with subsequent KTP laser prostatotomies (34 W
KTP laser), reported that the ‘hybrid’ group faired
much better in terms of recatheterization rates
(33% versus 70.5%). The advantages of the
‘hybrid’ technique over VLAP seen in early (18 h)
catheter removal in the ‘hybrid’ arm (80% versus
57%) were emphasized in a prospective double-
blind randomized trial.
16
Hybrid techniques eventually had to be
compared to the “gold standard,” TURP, and this
first took place in a randomized, control trial by
Carter et al. The hybrid technique in question
involved the initial delivery of 30 W of KTP laser
energy. The KTP laser was used to create bladder
neck incisions at the 5 or 7 o’clock positions, and
any median lobe or obstructive bladder neck
tissue was vaporized. Additional prostatotomies
were performed on any large prolapsing lateral
lobes. The prostate was subsequently treated with
Nd : YAG laser coagulation.
Early results demonstrated that expected post-
operative complications, such as irritating
symptoms and dysuria, were of similar frequency
between the ‘hybrid’ technique and TURP.
Moreover, the median post-operative duration of
catheterization was similar in both groups at 2
days.
17
Results at 1 year revealed a higher rate of
urethral stricture in the TURP arm (9.9% versus
2.1%). This was mainly attributed to the larger
scope diameter employed in the TURP procedure
(24 or 26Ch versus 21Ch). However, post-operative
urosepsis was more common in the laser group,
and this probably relates to the volume of necrotic
tissue left in situ at the end of the procedure.
IPSS, Qmax, post-void residuals and impro-
vements in LUTS were similar in each arm both
at 1 year and at 1.5 years. Importantly, only one
patient in each group required re-operation.
18
Shingleton et al.
19 reported on their three-year
results of 100 patients who had undergone either
hybrid KTP/Nd: YAG laser prostatectomy or TURP.
Both treatments produced equivalent improvements
in symptoms and flow rates, although the flow rate
improvement in the TURP group was lower than
expected from known published series. This might
be due to a rather limited resection with a change
in mean prostatic volume of only 3.3 cm
3 from
baseline to 36 months. The re-treatment rates were
also low with no re-operations in the TURP arm
compared with 6% for the laser cohort.
Later advancements in KTP lasers
The ‘hybrid technique’ enjoyed a brief period of
popularity that was eventually hampered by
prolonged operative times and limited tissue
ablation due to low power KTP energy available
in the mid 90s. Pure KTP laser vaporization
techniques soon took over, demonstrating a gradual
increase in their laser power and vaporization
ability over time.
Successful experimental animal studies for the
evaluation of pure KTP laser vaporization using
a 38 W system and a 60 W system on the canine
prostate model
9,20 preceded the first pilot clinical
study of the 60 W KTP laser vaporization in 10
patients at the Mayo Clinic.
21 The procedure was
performed using a 22 Ch continuous flow
cystoscope and sterile water as irrigation fluid.
Prostate glands of up to 60 mL of volume were
treated. Bleeding was successfully controlled by
defocusing the laser beam (3 - 4 mm) without
needing to switch to Nd:YAG laser for coagulation.
No irrigation was required post-operatively and
catheters were removed in less than 24 hours. At
24 hours, an impressive improvement in maximum
flow rate to 142% was noted and none of the
patients required re-catheterization. Results of a
three-month follow-up of three patients from this
group showed a mean AUA symptom score
reduction of 77%, mean peak flow rate increase of
166% and mean post-void residual volume
decrease of 82%.
21
Longer follow-up results from the same insti-
tution on the outcome of patients treated with 60
W KTP vaporization of the prostate were
published in 2000.
22 Patients with BPH having a
mean prostate volume of 43mL were treated, while
patients on retention were excluded. No patientPetros Sountoulides and Peter Tsakiris
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required blood transfusion or re-catheterization.
Only two patients (4%) were troubled by post-
operative delayed gross hematuria (6 - 8 weeks)
following strenuous physical activity. Another 7%
described mild dysuria, which settled without
treatment. In the longer term study, mean
improvement in Qmax was 278% and there was
a mean fall of 82% in the AUA symptom score at
a two-year follow-up of 14 patients. Retrograde
ejaculation was limited to just 9% of patients at
two years, possibly implying a very limited
resection of the bladder neck.
Going one step further, Carter et al., in their
series of 22 patients treated with 60 W KTP laser,
left six of the patients without a catheter post-
operatively, and they all managed to void freely.
23
Current experiences with the KTP laser
Despite the good results and its technical
simplicity, the 60W KTP laser had a size limitation
on the prostate glands treated (not exceeding 60
mL of weight) due to the less than ideal speed of
vaporization at 60 W. In order to improve the
speed of vaporization, a quasi-continuous-wave
KTP/532 laser was developed that emits an
average power of 80 W.
The 80 W KTP laser system (GreenLight
® PV,
American Medical Systems, Minnetonka, MN,
USA) described above uses a 70° side firing laser
fiber emitting laser at a 532 nm wavelength, which
is delivered through a small (21 - 23 F) continuous-
flow cystoscope. Total energy delivery may
amount to 200,000 Joules for a prostate of 70 - 80
mL, and the procedure is usually over in an hour
or so. PVP can be a catheter-free procedure.
However, even in cases where a catheter is left,
the duration of post-operative catheterization time
is minimal. Most patients can be treated on an
outpatient basis and may return home the same
evening. Post-operative irrigation is rarely nece-
ssary and may be applied to the occasional patient
with bleeding disorders or a very large prostate.
Pre-operative evaluation
The routine pre-operative evaluation of BPH
patients suffices for laser treatment with the KTP
laser. Particular attention should be paid to
accurate prostate volume measurement by TRUS,
particularly in large glands in order to estimate
parameters such as vaporization energy and
operative time.
24
Because there is no tissue specimen provided by
PVP, prostate cancer cannot be diagnosed based on
histological examination, thus continued post-
operative surveillance by digital rectal examination
and PSA are required. In cases of a pre-operative
elevated PSA or a suspicious DRE, a TRUS biopsy
should be done. Even so, some cases of prostate
cancer will still go undiagnosed because of normal
pre-operative PSA and DRE. However, there is
evidence deriving from a series of prostate cancers
incidentally diagnosed by TURP that these
cancers will eventually be missed by KTP
vaporization were usually managed with active
surveillance due to their low stage and moderate
Gleason score.
25 However, the clinical significance
of these cancers in the long-term is uncertain at
the present time.
Anesthesia options
A wide range of different options for delivering
anesthesia and analgesia to patients undergoing
PVP has been described. In a hospital setting,
light general anesthesia is usually preferred, since
regional anesthesia precludes a catheter-free
procedure. In most series, either regional or
general anesthesia was used depending on the
patient’s ASA score.
26,27
In an outpatient setting, a two-step anesthesia
process combining a cocktail of oral analgesics,
sedatives and non-steroidal anti-inflammatory
agents with bladder instillation of lidocaine has
been utilized. Local anesthesia in the form of a
periprostatic or pudendal nerve blocks using
lidocaine, bupivacaine or ropivacaine solutions
28
have also been described, but their efficacy and
safety have been questioned by others.
24
Outcomes of 80 W KTP laser prostatectomy
Initial results for the 80 W KTP laser came from
a small pilot series of 10 patients with a one-year
follow up.
29 The authors reported a reduction in
prostate volume of 27%, which is somewhat less
than the 40 - 50% reduction seen with TURP.
Results from uncontrolled clinical trials with a
maximum follow-up of one year followed.
In these trials, a total of 759 men (aged 45 - 90The Role of Lasers in the Treatment of benign Prostatic Hyperplasia
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years) with prostate volumes ranging from 15 -
250 mL (mean volume ~ 49.6) were treated. Mean
operative time was 53.7minutes, and the procedures
were performed under general or regional
anesthesia. Some studies excluded men with urinary
retention,
26 very large prostates or elevated PSA >
10 ng/dL.
30 In one study, patients with prostate
cancer were also enrolled.
31
Reduction in prostate volume ranged from
37%
30 to 53%
27,32 and was comparable to that after
TURP. Mean catheterization time ranged from 6 to
69 hours, while in one study 44 patients (32%)
were left without a catheter at the end of the
procedure.
30 No significant bleeding was encoun-
tered, and no blood transfusion was required
whatsoever. The efficacy of the procedure was
mirrored in the excellent Qmax and IPSS
improvements. Mean improvement in Qmax was
13.6 mL/sec from baseline, while there was a 14
point fall in mean IPSS.
In addition, results from a multicenter study
with a three-year follow-up of 139 men treated
with an 80 W KTP laser confirmed the overall
efficacy of the procedure. The significant diffe-
rences seen in the level of improvement for
patients with a baseline total PSA > 6 ng/dL were
explained by the vast difference in mean prostate
volume between the two subgroups (group 1, 48.3
mL; group 2, 83.1 mL). Still, these results may
raise scepticism about the efficacy of PVP in very
large prostates.
33
Regarding the safety of the procedure, the main
complications encountered in these series con-
sisted of urinary retention ranging from 1%
34 to
15.4%,
31 dysuria ranging from 6.2% to 30% and
minor haematuria (up to 18%). The occurrence of
retrograde ejaculation ranged between 36% and
55% in previously potent men.
The longest follow-up (five years) results publi-
shed by Malek et al.
35 raised some criticism
36,37
because of the high attrition (at five years, only 14
out of the original 94 patients were evaluated) and
the fact that only 15 of the patients studied were
actually treated with the “new” 80 W KTP laser.
Complications described were transient dysuria
(6%), hematuria (3%), bladder neck contracture
(2%), and retention (1%). Whatever the signifi-
cance of these shortcomings, at five years, 79% of
treated patients had maintained a 100% impro-
vement of their Qmax from baseline, while all
patients maintained an improvement of at least
50% in their symptoms (IPSS) from baseline.
35
A large series reporting complication rates after
PVP comes from Switzerland.
38 A total of 406
patients including men in retention, on antico-
agulation therapy and of an advanced age were
treated and followed-up for three years. No serious
bleeding or TURP-syndrome was observed. Bladder
irrigation was required for 9.6% of patients, most of
whom were on anticoagulants. Post-operative
retention and re-catheterization rate was 9.6% and
strongly correlated with age but not with prostate
volume at baseline. Also, in 2.2% of the procedures,
a transient conversion to TURP for electrocoa-
gulation of troublesome capsular bleeding was
necessary. Late complications included a 6.3%
urethral stricture rate, while 21 patients (5.2%)
experienced recurrence of LUTS due to insufficient
initial vaporization.
a) High-risk patients & patients on anticoagulants
Theoretically, one major advantage of PVP is
that a virtually bloodless tissue ablation technique
can be applied to high-risk patients relatively
safely. Evidence of this comes from a two-center
study evaluating a total of 66 men with an ASA
score of 3 or greater.
39
Safety results were encouraging as there were
no blood transfusion requirements and no fluid
absorption. There was an 11% need for re- cathe-
terization, while the results on voiding parameters
revealed an impressive 222% improvement in Qmax
from baseline in one year and a mean reduction in
IPSS of about 14 points at one year follow-up.
Similar efficacy results were presented in
another study.
40 Interestingly, the mean operative
time was only 25.6 minutes, which is largely
disproportionate to the mean prostate volume at
baseline (72.5 mL). However, there are no data on
mean prostate volume reduction or re-operation
rates.
40
A major cohort of patients considered to be at
high-risk for bleeding and transfusion are those
on anticoagulation therapy. Currently, urologists
are faced with an increasing number of patients
requiring prostatectomy while on oral anticoa-
gulation therapy. Unfortunately, conventional
TURP has failed to provide acceptable safety forPetros Sountoulides and Peter Tsakiris
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these patients, for the transfusion rate has been
exceeding 30%.
41 The most commonly-used perio-
perative management in anticoagulated patients is
discontinuation of oral anticoagulant therapy
several days before TURP and conversion to
conventional or low molecular weight heparin
(LMWH) as bridging therapy perioperatively.
However, perioperative use of LMWH has led to
a significant increase in catheterization time and
hospital stay while maintaining an unacceptable
transfusion rate of 20%.
42
The safety of PVP in men with serious co-
morbidities necessitating continuous anticoagul-
ation was assessed in a series of 116 men on
coumadin, aspirin or clopidogrel. This group of
men on oral anticoagulation was compared to a
control group of men undergoing PVP without
taking anticoagulants.
43
Results showed similar efficacy in terms of
voiding parameters between the two groups. In
the group of patients on anticoagulants, no
thromboembolic or bleeding complications were
observed and no blood transfusions were re-
quired. The only difference was a higher rate of
transient 24 hour post-operative irrigation (17% vs
5.4% in the control group) resulting in a longer
catheterization time. Post-operative retention rates
were slightly higher than previously reported
(~12% in both groups), while a 40% decline in
PSA values at two years was observed in both
groups, indicating that an equal amount of tissue
was removed.
b) Patients with large prostates
The issue whether very large prostates could be
adequately treated with KTP laser within a
reasonable time with acceptable reoperation rates
was addressed by Sandhu et al.,
44 who evaluated
the safety and efficacy of the 80 W KTP laser in
64 patients with prostate volumes in excess of 60
mL. Twenty-eight percent of patients were in
retention pre-operatively, and some of them
probably would have been otherwise denied a
TURP because of their high ASA score.
Mean prostate volume was 101 mL and mean
operative time was 123 minutes. However, two
patients required staged procedures because of
their lengthy prostatic urethra. Ninety-five
percent of patients had their catheters removed
within 23 hours. Three patients needed re-
catheterization in the early post-operative period,
while the one year re-operation rate was 5%.
Regarding efficacy, Qmax improved from 7.9 mL/
sec to 18.9 mL/sec in one year, while IPSS declined
from 18.4 at baseline to 6.7 post-operatively.
A modified vaporization-incision technique (VIT)
in large-volume prostatectomy was evaluated in 20
patients with high-volume prostates, and results
were compared with those in 64 prior patients with
similar volume prostates who had been treated
with standard laser prostatectomy. However, IPSS
and flow rates at post-operative months 1 and 3
showed no significant differences between the two
techniques .
45
c) Patients in retention
Another major issue is the outcome of patients
with indwelling catheters due to urinary
retention. Historically, this subgroup of patients is
plagued with a higher complication rate and,
sometimes, a poorer outcome in terms of voiding
parameters. A study comparing the outcome of 70
patients with refractory retention and 113 men
with BPH but no retention was conducted.
Functional outcomes and incidence of perio-
perative complications were similar in the two
groups. In particular, the post-operative retention
rate observed was comparable between patients
with and without retention (12.9% vs 10.6%,
respectively). Moreover, there were no statistically
significant differences between the two groups
with regards to Qmax, IPSS, or PVR.
46
A direct comparison between PVP and TURP in
the treatment of men presenting with acute
urinary retention revealed similar efficacy results
at one year follow-up, although IPSS scores were
better for the TURP arm in the short term (three
months).
47
PVP compared to TURP
Photoselective vaporization of the prostate
represents the latest development in technology
for the treatment of BPH, and it emerges as an
alternative to TURP. However, since the end of
2005, there was only one non-randomized controlled
study published
48 to prospectively compare PVP
with conventional TURP as the reference treatment
for BPH. In this study, PVP was superior to TURPThe Role of Lasers in the Treatment of benign Prostatic Hyperplasia
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in terms of catheter drainage time and hospital
stay, while PVP was somewhat lengthier than
TURP. Intraoperative bleeding was a problem in
10.8% of TURP cases but not in PVP. Early
(six-month) results revealed similar improvements
in voiding parameters. However, prostate volume
reduction was significantly greater in the TURP
arm, thus questioning the durability of longer-term
PVP results. Nevertheless, the mean follow-up of
six months a priori precludes any conclusions on
durability.
The first randomized, although incomplete,
study of 76 patients treated by either TURP or
PVP and then followed-up for at least six weeks
showed similar results in terms of voiding parameters
(Qmax-IPSS) for the two arms.
49 Although data
were preliminary and results biased in many ways
(men with prostate volumes > 85 mL, on retention
or on anticoagulants were excluded and the
surgeons were inexperienced in PVP), it was clear
that PVP was superior to TURP in terms of earlier
catheter removal, hospital stay and early
complication rate. Data on re-operation rates and
long-term efficacy of the procedures were, unfor-
tunately, not available.
Interim results from the same trial were recently
published.
50 Improvements in Qmax and symptom
scores were equivalent for both treatments, and
although the number of patients available for
evaluation at one year (n = 59) was still far from
optimal for drawing substantiated conclusions,
early re-operation rate was in favor of TURP.
However, in total, early complications were fewer
and less severe in the PVP arm.
A recent prospective non-randomized study
comparing PVP (249 patients) with TURP (129
patients) revealed a significant difference in mean
operative time between the two procedures (73’
for PVP vs 53’ for TURP), which was partly due
to the larger prostates assigned to the PVP group.
Still, there is evidence that the estimated speed of
tissue vaporization with the KTP laser is lower
than the tissue resection rate with the standard
TURP.
In this study, KTP vaporization confirmed its
superiority with respect to intraoperative safety
and earlier discharge from the hospital, yet
although both treatments resulted in similar
improvements in IPSSs, the Qmax was higher for
TURP in the two-year follow-up and there was
also a trend for higher re-operation rates for PVP
in the long-run.
51 Therefore, there is an issue
regarding the long-term durability of the pro-
nounced short-term improvements in micturition
parameters achieved with PVP.
The major advantages and drawbacks of PVP
compared to TURP are listed in Table 1.
Learning curve
The learning curve for a procedure plays a
crucial role in its overall applicability and cost-
effectiveness. Evidence to this is the significantly
shorter learning curve for the KTP laser as
opposed to HoLEP, and this is the main reason for
the popularity and wider applicability of the
former.
52 However, there are intrinsic difficulties
Table 1. Major Advantages and Disadvantages of PVP Compared to TURP
PVP TURP
Safer for larger prostates (> 100 mL) with no risk of
dilutional hyponatremia
Risk of fluid absorption-TURP syndrome when
resection time > 90 min
Lengthier procedure-slower vaporization speed
( 0.5 ～ gr/min)
Shorter operation time-higher resection speed
(up to 1 gr/min)
Minimal to no catheterization time & reduced hospital
stay (day-case procedure)
Catheterization time of at least 2-3 days, resulting to
prolonged hospital stay
Reduced risk of retrograde ejaculation (35 - 55%) Significant risk of retrograde ejaculation (53 - 75%)
Absence of histological evaluation of removed prostatic
tissue
Ability to detect (incidental) prostate cancer
Higher reoperation rates More durable results over time
PVP, photoselective vaporization of the prostate; TURP, transurethral resection of the prostate.Petros Sountoulides and Peter Tsakiris
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in accurately quantifying the concept of a learning
curve. It relies on subjective estimations of the
surgeon and is biased by the level of his or her
experience and the quality of training and
education that each surgeon has received by their
own mentors.
Nevertheless, KTP laser vaporization is con-
sidered easier to learn and perform than TURP.
Most urologists would feel comfortable performing
TURPs after about 50 procedures.
50 Rajbabu et al.
24
consider a series of 10 - 20 procedures sufficient for
gaining competence using the 80 W KTP laser on
small prostates, while others
50 believe that five
cases are enough in order for one to safely tackle
small glands (< 40 mL) with reasonable median
lobes. Larger prostates can be confidently managed
after about 20 cases. Meanwhile, a short mentor-
ship training period is essential in order to be able
to adequately perform PVP.
Cost implementation of PVP treatment
The issue of cost and effectiveness of various
treatment options for BPH has been widely,
however insufficiently, addressed as a whole. This
is a difficult task to accomplish since the general
concept of “costs” related to a certain treatment or
intervention is quite heterogeneous. One has to
take into consideration both the direct (office
visits, hospital costs, imaging studies, etc.) and the
indirect costs (absence from work, lost earnings)
and also incorporate the costs of treatment failures
and re-treatments. Other related issues are the
prospective nature of such a study with long-term
follow-up in order to reach meaningful results,
the actual differences that exist in health systems
and patients’ perspectives and backgrounds
throughout the globe.
There is no doubt that the cost per year for BPH
treatment is certainly less for medical treatments
than for invasive surgical procedures. The cost of
TURP was estimated to be between 3,874 and
8,608 US dollars, while the direct cost of medical
therapy ranges from 73 to 974 US dollars per
patient per year.
53
In the long run, however, surgical treatments
like TURP, especially for patients younger than 70
years of age,
54 seem preferable as they appear to
be more cost-effective due to the increased annual
maintenance costs of oral medication. Additionally,
the high discontinuation rate (47 - 58%) observed
for alpha-blockers in the first three years
55 further
contributes to the diminished long term cost-
effectiveness of medications for BPH. The treat-
ment pathway, starting with medications and
ultimately leading to a TURP or an open procedure,
actually carries the highest lifetime treatment cost.
56
Furthermore, this pathway results in fewer patients
being operated on for BPH with advanced age,
major co-morbidities and larger prostates at the
time of surgery.
57 The evolution of PVP will most
likely change the landscape in both the surgical
and medical treatment of BPH, but this remains
to be seen.
Reviewing the very little available literature so
far regarding the cost-effectiveness of PVP
treatment for BPH, one has to commend the study
by Stovsky et al. comparing the costs and clinical
outcomes of five interventions for BPH, namely
PVP, ILC, TURP, TUNA and TUMT.
58
Using the decision-analytic Markov model, the
authors came to the conclusion that PVP is,
overall, less costly than other procedures. The cost
savings stemmed from the lower rates of adverse
events and re-treatment of PVP, but these
conclusions are somewhat premature and certainly
hampered by the limited number of prospective
long-term studies of PVP.
Similar conclusions were reached in two studies
coming from the same group in Australia. In these
studies, the direct cost of PVP as a day procedure
was estimated to be 3368 AU dollars, while the
cost of TURP was 4291 AU dollars.
49 Overall, PVP
was considered 22% less costly compared to
TURP, mainly because of the shorter hospital stay
and complication rate. However, cost analysis was
done by taking a random sample of five cases
from each group, and the short follow-up period
and available patients (59 patients at 12 months)
were inadequate for substantial conclusions.
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It is certainly early to draw conclusions about
the cost-effectiveness of PVP in the treatment of
BPH since long-term prospective trials assessing
various parameters of “cost” and “effect” are
lacking. The heavy financial cost of initial capital
investment for the laser base and the disposables
(fibers) should be balanced against the savings
stemming from reduced hospital stay and fewer
complications. Keeping all of this in mind,The Role of Lasers in the Treatment of benign Prostatic Hyperplasia
Yonsei Med J Vol. 49, No. 2, 2008
Alivizatos et al. concluded that although preliminary
results of cost-analysis studies of PVP are in favor
of PVP versus TURP, further evidence is certainly
needed to support this.
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High Performance System (HPS)
The 80 W KTP laser system has proven to
possess sustained efficacy and safety in the
treatment of moderate to large prostates. However,
the vaporization procedure for very large glands
remained tedious and time-consuming due to the
limited rate of power delivered per unit of time. In
order to overcome these limitations, the new and
improved GreenLight High Performance System
(HPS) was recently introduced.
This advanced diode-pumped solid state laser
system delivers the same 532 nm wavelength
within a power setting of 20 - 120W instead of the
30 - 80 W average power level of its predecessor.
This 50% increase in power results in potentially
increased vaporization efficacy.
One of the differences between this system and
the 80 W KTP laser is that maximum focus with
negligible divergence of power is now maintained
even within a distance of 3 - 5 mm from the fiber,
allowing for vaporization to be consistently efficient
despite variable changes in distance between fiber
and tissue.
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The fiber is covered with a highly reflective
coating in order to limit the back-scatter effect and
the resulting inadvertent ablation of tissue.
The HPS system also incorporates a dual-power
mode function using two pedals; one for vaporizing
tissue (60 - 120 W) and another for coagulating at
lower power settings (20 - 40 W), while power is
now delivered in 10 W instead of 5 W increments.
Initial experience with the HPS 120W is described
as "exciting",
24 but further results from large trials
are necessary in order to evaluate the advantages
and potential shortcomings of this system.
CONCLUSIONS
Recent improvements in laser technology and a
better understanding of the interactions of different
laser wavelengths and power settings with tissue
have led to the development of promising new
treatment modalities. The evolution of laser
prostatectomy seems to put into doubt the “gold
standard” surgical treatment, TURP, for BPH.
The new generation of high-powered KTP
lasers is currently gaining popularity at a fast
speed because of its ability to create a prostate
cavity almost bloodlessly along with the added
benefit of a small learning curve and the prospect
of a day-case, catheter-free procedure.
On the other hand, the procedure can be
lengthy at times, while the laser and installation
costs can be difficult to justify since KTP lasers
have limited urological applications thus far.
Moreover, issues regarding the sustained long-
term results and re-operation rates have to be
further addressed in future trials. Furthermore,
there is lack of evidence regarding direct com-
parison of the KTP laser vaporization with other
laser-based treatments for BPH, such as holmium
/thulium resection-enucleation.
Whether or not KTP laser vaporization will
stand to compete with TURP and other emerging
minimally invasive treatment options for BPH in
the long run is a question whose answer depends
on the quality of scientific evidence that will be
presented in the near future.
REFERENCES
1. Rassweiler J, Schulze M, Stock C, Teber D, De La
Rosette J. Bipolar transurethral resection of the prostate-
technical modifications and early clinical experience.
Minim Invasive Ther Allied Technol 2007;16:11-21.
2. Yoon CJ, Kim JY, Moon KH, Jung HC, Park TC.
Transurethral resection of the prostate with a bipolar
tissue management system compared to conventional
monopolar resectoscope: one-year outcome. Yonsei
Med J 2006;47:715-20.
3. Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK.
Evaluation of short term clinical effects and presump-
tive mechanism of botulinum toxin type A as a
treatment modality of benign prostatic hyperplasia.
Yonsei Med J 2006;47:706-14.
4. Barber NJ, Muir GH. High-power KTP laser pros-
tatectomy: the new challenge to transurethral resection
of the prostate. Curr Opin Urol 2004;14:21-5.
5. Lee R, Gonzalez RR, Te AE. The evolution of photo-
selective vaporization prostatectomy (PVP): advancing
the surgical treatment of benign prostatic hyperplasia.
World J Urol 2006;24:405-9.
6. Te AE. The next generation in laser treatments and thePetros Sountoulides and Peter Tsakiris
Yonsei Med J Vol. 49, No. 2, 2008
role of the GreenLight high-performance system laser.
Rev Urol 2006;8 (Suppl 3):S24-30.
7. Rajbabu K, Dudderidge T, Barber N, Walsh K, Muir G.
Evaluation of ideal irrigation fluid in ‘Greenlight’
photoselective vapourization of the prostate. Prostate
Cancer Prostatic Dis 2007;10:101-3.
8. Barber NJ, Zhu G, Donohue JF, Thompson PM, Walsh
K, Muir GH. Use of expired breath ethanol measurements
in evaluation of irrigant absorption during high-power
potassium titanyl phosphate laser vaporization of
prostate. Urology 2006;67:80-3.
9. Kuntzman RS, Malek RS, Barrett DM, Bostwick DG.
High-power (60-watt) potassium-titanyl-phosphate laser
vaporization prostatectomy in living canines and in
human and canine cadavers. Urology 1997;49:703-8.
10. Costello AJ, Johnson DE, Bolton DM. Nd:YAG laser
ablation of the prostate as a treatment for benign
prostatic hypertrophy. Lasers Surg Med 1992;12:121-4.
11. Hoffman RM, MacDonald R, Slaton JW, Wilt TJ. Laser
prostatectomy versus transurethral resection for treating
benign prostatic obstruction: a systematic review. J
Urol 2003;169:210-5.
12. Watson G. Contact laser prostatectomy. World J Urol
1995;13:115-8.
13. Miki T, Kojima Y, Nonomura N, Matsumiya K, Kokado
Y, Yoshioka T, et al. Transurethral visual laser ablation
of the prostate for benign prostatic hyperplasia using
a KTP/YAG laser. Int J Urol 1997;4:576-9.
14. Shingleton WB, Terrell F, Renfroe L, Kolski J, Fowler
JE Jr. Low-power v high-power KTP laser: improved
method of laser ablation of prostate. J Endourol 1999;
13:49-52.
15. Kollmorgen TA, Malek RS, Barrett D. Laser pros-
tatectomy: two and a half years’ experience with
aggressive multifocal therapy. Urology 1996;48:217-22.
16. Langley SE, Gallegos CR, Moisey CU. A prospective
randomized trial evaluating endoscopic Nd:YAG laser
prostate ablation with or without potassium titanyl
phosphate (KTP) laser bladder neck incision. Br J Urol
1997;80:880-4.
17. Carter A, Sells H, Speakman M, Ewings P, MacDonegh
R, O’Boyle P. A prospective randomized controlled
trial of hybrid laser treatment or transurethral resection
of the prostate, with a 1-year follow-up. BJU Int 1999;
83:254-9.
18. Pearcy RM, Carter A, Sells H, O’Boyle P. Hybrid KTP/
Nd:YAG laser treatment of the prostate versus TURP:
18 months’ follow-up data. BJU Int 1999;83 (Suppl 4):
37.
19. Shingleton WB, Farabaugh P, May W. Three-year
follow-up of laser prostatectomy versus transurethral
resection of the prostate in men with benign prostatic
hyperplasia. Urology 2002;60:305-8.
20. Kuntzman RS, Malek RS, Barrett DM, Bostwick DG.
Potassium-titanyl-phosphate laser vaporization of the
prostate: a comparative functional and pathologic
study in canines. Urology 1996;48:575-83.
21. Malek RS, Barrett DM, Kuntzman RS. High-power
potassium-titanyl-phosphate (KTP/532) laser vaporiza-
tion prostatectomy: 24 hours later. Urology 1998;51:
254-6.
22. Malek RS, Kuntzman RS, Barrett DM. High power
potassium-titanyl-phosphate laser vaporization pros-
tatectomy. J Urol 2000;163:1730-3.
23. Carter A, Sells H, O’Boyle PJ. High-power KTP laser
for the treatment of symptomatic benign prostatic
enlargement. BJU Int 1999;83:857-8.
24. Rajbabu K, Muir GH. GreenLight photoselective
vaporization of prostate - a technical review. Prostate
Cancer Prostatic Dis 2007;10 Suppl 1:S6-9.
25. Haley R, Boddy J, Wharton I, Sami T, Ryan P, Devarajan
R. A retrospective audit of TURP to assess the potential
impact of Green Light Laser surgery on the diagnosis
of prostate cancer [abstract]. Eur Urol Suppl 2007;6:195.
26. Bachmann A, Ruszat R, Wyler S, Reich O, Seifert HH,
Müller A, et al. Photoselective vaporization of the
prostate: the basel experience after 108 procedures. Eur
Urol 2005;47:798-804.
27. Sarica K, Alkan E, Lüleci H, Taşci AI. Photoselective
vaporization of the enlarged prostate with KTP laser:
long-term results in 240 patients. J Endourol 2005;19:
1199-202.
28. Kaplan SA. Expanding the role of photoselective
vaporization of the prostate. Rev Urol 2006;8 Suppl
3:S3-8.
29. Hai MA, Malek RS. Photoselective vaporization of the
prostate: initial experience with a new 80 W KTP laser
for the treatment of benign prostatic hyperplasia. J
Endourol 2003;17:93-6.
30. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO,
Hai MA, et al. Photoselective vaporization of the
prostate for the treatment of benign prostatic hyper-
plasia: 12-month results from the first United States
multicenter prospective trial. J Urol 2004;172:1404-8.
31. Sulser T, Reich O, Wyler S, Ruszat R, Casella R,
Hofstetter A, et al. Photoselective KTP laser vapori-
zation of the prostate: first experiences with 65
procedures. J Endourol 2004;18:976-81.
32. Dincel C, Samli M, Guler C, Demirbas M, Karalar M.
Plasma kinetic vaporization of the prostate: clinical
evaluation of a new technique. J Endourol 2004;18:293-
8.
33. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO,
Hai MA. Impact of prostate-specific antigen level and
prostate volume as predictors of efficacy in photo-
selective vaporization prostatectomy: analysis and
results of an ongoing prospective multicentre study at
3 years. BJU Int 2006;97:1229-33.
34. Volkan T, Ihsan TA, Yilmaz O, Emin O, Selcuk S,
Koray K. et al. Short term outcomes of high power (80
W) potassium-titanyl-phosphate laser vaporization of
the prostate. Eur Urol 2005;48:608-13.
35. Malek R, Kuntzman R, Barrett DM. Photoselective
potassium-titanyl-phosphate laser vaporization of the
benign obstructive prostate: observations on long-term
outcomes. J Urol 2005;174:1344-8.The Role of Lasers in the Treatment of benign Prostatic Hyperplasia
Yonsei Med J Vol. 49, No. 2, 2008
36. Bachmann A, Ruszat R. The KTP-(greenlight-) laser-
principles and experiences. Minim Invasive Ther Allied
Technol 2007;16:5-10.
37. Reich O, Gratzke C, Stief CG. Techniques and long-
term results of surgical procedures for BPH. Eur Urol
2006;49:970-8, discussion 978.
38. Ruszat R, Wyler S, Forster T, Sulser T, Bachmann A.
Complications of photoselective vaporization of the
prostate [abstract]. Eur Urol Suppl 2007;6:136.
39. Reich O, Bachmann A, Siebels M, Hofstetter A, Stief
CG, Sulser T. High power (80W) potassium-titanyl-
phosphate laser vaporization of the prostate in 66 high
risk patients. J Urol 2005;173:158-60.
40. Fu WJ, Hong BF, Wang XX, Yang Y, Cai W, Gao JP.
Evaluation of greenlight photoselective vaporization of
the prostate for the treatment of high-risk patients with
benign prostatic hyperplasia. Asian J Androl 2006;8:
367-71.
41. Parr NJ, Loh CS, Desmond AD. Transurethral resection
of the prostate and bladder tumour without with-
drawal of warfarin therapy. Br J Urol 1989;64:623-5.
42. Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J,
Duvdevani M, et al. The efficacy and safety of perio-
perative low molecular weight heparin substitution in
patients on chronic oral anticoagulant therapy under-
going transurethral prostatectomy for bladder outlet
obstruction. J Urol 2002;168:610-3, discussion 614.
43. Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser
TC, et al. Safety and effectiveness of photoselective
vaporization of the prostate (PVP) in patients on
ongoing oral anticoagulation. Eur Urol 2007;51:1031-8,
discussion 1038-41.
44. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA,
Te AE. High-power potassium-titanyl-phosphate photo-
selective laser vaporization of prostate for treatment of
benign prostatic hyperplasia in men with large prostates.
Urology 2004;64:1155-9.
45. Sandhu JS, Te AE. Photoselective vaporization of the
prostate: the vaporization incision technique for large
volume prostates [abstract]. J Urol 2005;173 (4 Suppl):
366.
46. Ruszat R, Wyler S, Seifert HH, Reich O, Forster T,
Sulser T, et al. Photoselective vaporization of the
prostate: subgroup analysis of men with refractory
urinary retention. Eur Urol 2006;50:1040-9.
47. Hirst G, Edwards M, James W, Bose P. Comparison of
TURP and photoselective vaporization of the prostate
(PVP) in men presenting with painful acute urinary
retention [abstract]. Eur Urol Suppl 2007;6:192.
48. Bachmann A, Schürch L, Ruszat R, Wyler SF, Seifert
HH, Müller A, et al. Photoselective vaporization (PVP)
versus transurethral resection of the prostate (TURP):
a prospective bi-centre study of perioperative morbidity
and early functional outcome. Eur Urol 2005:48:965-71,
discussion 972.
49. Bouchier-Hayes DM, Anderson P, Van Appledorn S,
Bugeja P, Costello A. KTP laser versus transurethral
resection: early results of a randomized trial. J Endourol
2006;20:580-5.
50. Bouchier-Hayes DM. Photoselective vaporization of the
prostate-towards a new standard. Prostate Cancer
Prostatic Dis 2007;10 Suppl 1:S10-4.
51. Ruszat R, Lehmann K, Wyler S, Forster T, Schurch L,
Straumann U, et al. 24 months results of a prospective
Bi-Center study of photoselective vaporization of the
prostate (PVP) versus transurethral resection of the
prostate (TURP) [abstract]. Eur Urol Suppl 2007;6:192.
52. de la Rosette J, Alivizatos G. Lasers for the treatment
of bladder outlet obstruction: are they challenging
conventional treatment modalities? Eur Urol 2006;50:
418-20.
53. Taub DA, Wei JT. The economics of benign prostatic
hyperplasia and lower urinary tract symptoms in the
United States. Curr Urol Rep 2006;7:272-81.
54. Chirikos TN, Sanford E. Cost consequences of surveil-
lance, medical management or surgery for benign
prostatic hyperplasia. J Urol 1996;155:1311-6.
55. de la Rosette J, Kortmann BB, Rossi C, Sonke GS,
Floratos DL, Kiemeney LA. Long-term risk of re-treat-
ment of patients using alpha-blockers for lower urinary
tract symptoms. J Urol 2002;167:1734-9.
56. DiSantostefano RL, Biddle AK, Lavelle JJ. The long-
term cost effectiveness of treatments for benign prostatic
hyperplasia. Pharmacoeconomics 2006;24:171-91.
57. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso
JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ. The
impact of medical therapy on surgery for benign
prostatic hyperplasia: a study comparing changes in a
decade (1992-2002). BJU Int 2005;96:1045-8.
58. Stovsky MD, Griffiths RI, Duff SB. A clinical outcomes
and cost analysis comparing photoselective vaporiza-
tion of the prostate to alternative minimally invasive
therapies and transurethral prostate resection for the
treatment of benign prostatic hyperplasia. J Urol 2006;
176:1500-6.
59. Alivizatos G, Skolarikos A. Photoselective vaporization
of the prostate. Review of cost implementation to BPH
treatment. Prostate Cancer Prostatic Dis 2007;10:S15-20.
60. Te AE. Current state of the art photoselective vapori-
zation prostatectomy: laser therapy for benign prostatic
hyperplasia. Prostate Cancer Prostatic Dis 2007;10:S2-5.